

Ogalvibart

Cat. No.:	HY-145644
CAS No.:	2599039-60-6
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model ^[1] .								
IC₅₀ & Target	SARS-CoV-2 ^[1] .								
In Vivo	<p>Ogalvibart (C-135-LS; 10 mg/kg; 75 days before infection) in combination with 10 mg/kg C144LS can effectively block development of COVID-19 in the rhesus disease model^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Rhesus macaques (3-11 years old)^[1].</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg (in combination with 10 mg/kg C144LS)</td> </tr> <tr> <td>Administration:</td> <td>75 days before infection</td> </tr> <tr> <td>Result:</td> <td>Protected a subset of animals whose infectious challenge was 75 days post administration from disease.</td> </tr> </table>	Animal Model:	Rhesus macaques (3-11 years old) ^[1] .	Dosage:	10 mg/kg (in combination with 10 mg/kg C144LS)	Administration:	75 days before infection	Result:	Protected a subset of animals whose infectious challenge was 75 days post administration from disease.
Animal Model:	Rhesus macaques (3-11 years old) ^[1] .								
Dosage:	10 mg/kg (in combination with 10 mg/kg C144LS)								
Administration:	75 days before infection								
Result:	Protected a subset of animals whose infectious challenge was 75 days post administration from disease.								

REFERENCES

[1]. Beddingfield BJ, et al. Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies. Front Cell Infect Microbiol. 2021 Nov 18;11:753444.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA